anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
OBJECTIVE: This study aimed to analyze myocardial work in patients with atrial fibrillation (AF) using a noninvasive pressure strain loop (PSL) technique to provide a basis for the quantitative assessment of left ventricular (LV) systolic function.
METHODS: LV myocardial work of 107 AF patients (56 with paroxysmal atrial fibrillation and 51 with persistent atrial fibrillation) and 55 healthy individuals were assessed by the noninvasive PSL and then compared.
RESULTS: Global longitudinal strain (GLS) in absolute values, global work index (GWI), global constructive work (GCW), and global work efficiency (GWE) were significantly lower in the AF group than control group, whereas peak strain dispersion (PSD) and global wasted work (GWW) were significantly higher (P < .05). Further subdivision according to the AF type revealed that, compared with the controls, GLS in absolute values and GWE decreased significantly; PSD and GWW increased significantly in the paroxysmal AF group (P < .05). Nevertheless, GWI and GCW were not significantly different between paroxysmal AF and control groups (P > .05). Compared to paroxysmal AF, persistent AF induced a further decrease in absolute GLS and GWE and a further increase in GWW (P < .05), but PSD did not increase further (P > .05). Multiple linear regression analysis showed that GWI and GCW were independently associated with systolic blood pressure. GWW was associated with types of AF and left atrial volume index (LAVI). GWE was correlated with age, types of AF, disease duration, and LAVI. Receiver operating characteristic curve analysis showed that the area under the curve predicting myocardial injury was higher for GWE and GWW than for GLS (area under the curve:  .880,  .846, and  .821, respectively).
CONCLUSIONS: Non-invasive PSL can quantitatively assess LV systolic function in patients with different kinds of AF and detect early subclinical myocardial injury in patients with paroxysmal AF. GWE and GWW outperform GLS and LV ejection fraction when assessing myocardial injury. Systolic blood pressure, type of AF, LVAI, disease duration, and age may be associated with myocardial injury in patients with AF.
Background Contrast-enhanced US (CEUS) can be used preoperatively for evaluating muscle invasion in bladder cancer, which is important for determining appropriate treatment. However, diagnostic criteria for assessing this at CEUS have not been standardized. Purpose To develop and validate a CEUS Vesical Imaging Reporting and Data System (VI-RADS) for evaluating muscle invasion in bladder cancer. Materials and Methods This single-center prospective study consecutively enrolled patients with suspected bladder cancer. Participants underwent transabdominal or intracavity CEUS between July 2021 and May 2023. Participants were divided into a training set and a validation set at a 2:1 ratio based on the chronologic order of enrollment. The training set was used to identify major imaging features to include in CEUS VI-RADS, and the likelihood of muscle invasion per category was determined using a pathologic reference standard. The optimal VI-RADS category cutoff for muscle invasion was determined with use of the maximum Youden index. The validation set was assessed by novice and expert readers and used to validate the diagnostic performance and interreader agreement of the developed system. Results Overall, 126 participants (median age, 64 years [IQR, 57-71 years]; 107 male) and 67 participants (median age, 64 years [IQR, 56-69 years]; 49 male) were included in the training and validation set, respectively. In the training set, the optimal CEUS VI-RADS category cutoff for muscle invasion was VI-RADS 4 or higher (Youden index, 0.77). In the validation set, CEUS VI-RADS achieved good performance for both novice and expert readers (area under the receiver operating characteristic curve, 0.80 [95% CI: 0.70, 0.90] vs 0.88 [95% CI: 0.80, 0.97]; P = .09). The interreader agreement regarding the evaluation of CEUS VI-RADS category was 0.77 (95% CI: 0.65, 0.85) for novice readers, 0.87 (95% CI: 0.79, 0.92) for expert readers, and 0.78 (95% CI: 0.70, 0.84) for all readers. Conclusion The developed CEUS VI-RADS showed good performance and interreader agreement for the assessment of muscle invasion in bladder cancer. Chinese Clinical Trial Registry no. ChiCTR2100049435 © RSNA, 2024 Supplemental material is available for this article. See also the editorial by Morrell in this issue.
<P>PROBLEM TO BE SOLVED: To provide a collagen synthesis accelerator.  <P>SOLUTION: This collagen synthesis accelerator contains a powder or an extract, as it is or roughly purified or purified, of at least one plant selected from among plants of the genera Pfaffia and Ajuga as the effective component. The accelerator accelerates the in vivo biosynthesis of collagen, can restore the tissue synthesis function, can improve the fatigue of tissue and the lowering of functions accompanying to the change by aging, and brings about the effects on various dermal wounds (e.g. bedsores), osteoporosis, etc. Since the accelerator contains a crude drug-derived component as the effective one, it does not cause side effects and can be administered over a long time.  <P>COPYRIGHT: (C)2004,JPO
Sarilumab 150 mg subcutaneous (SC) injection once every 2 weeks (q2w) in combination with MTX and folic acid in double-blind period up to Week 24 followed by single-blind period in which participants continued with the same treatment up to Week 52. Participants with inadequate response (defined as less than 20% improvement from baseline on 2 consecutive visits \[at least 4 weeks apart\] in either tender joint count \[TJC\] or swollen joint count \[SJC\], or with any other clear lack of efficacy based on investigator's judgment) by Week 16, were rescued with open label sarilumab 200 mg q2w treatment.
The patient's primary care provider (PCP) will deliver a brief intervention using motivational interviewing and shared decision making, in a one time 9-minute intervention integrated into an office visit for asthma. PCPs will follow a 4-step script tailored to erroneous asthma and inhaled corticosteroid (ICS) beliefs, as well as ACQ score, measured just prior to the office visit.
BACKGROUND: Recent evidence suggests that certain fetal anomalies detected upon prenatal ultrasound screenings are associated with autism spectrum disorder (ASD). In this cross-sectional study, we aimed to identify genetic variants associated with fetal ultrasound anomalies (UFAs) in children with ASD.
METHODS: The study included all children with ASD who are registered in the database of the Azrieli National Center of Autism and Neurodevelopment and for whom both prenatal ultrasound and whole exome sequencing (WES) data were available. We applied our in-house integrative bioinformatics pipeline, AutScore, to these WES data to prioritize rare, gene-disrupting variants (GDVs) probably contributing to ASD susceptibily. Univariate statistics and multivariable regression were used to assess the associations between UFAs and GDVs identified in these children.
RESULTS: The study sample comprised 126 children, of whom 43 (34.1%) had at least one UFA detected in the prenatal ultrasound scan. A total of 87 candidate ASD genetic variants were detected in 60 children, with 24 (40%) children carrying multiple variants. Children with UFAs were more likely to have loss-of-function (LoF) mutations (aOR = 2.55, 95%CI: 1.13-5.80). This association was particularly noticeable when children with structural anomalies or children with UFAs in their head and brain scans were compared to children without UFAs (any mutation: aOR = 8.28, 95%CI: 2.29-30.01; LoF: aOR = 5.72, 95%CI: 2.08-15.71 and any mutation: aOR = 6.39, 95%CI: 1.34-30.47; LoF: aOR = 4.50, 95%CI: 1.32-15.35, respectively). GDVs associated with UFAs were enriched in genes highly expressed across all tissues (aOR = 2.76, 95%CI: 1.14-6.68). There was a weak, but significant, correlation between the number of mutations and the number of abnormalities detected in the same children (r = 0.21, P = 0.016).
CONCLUSIONS: The results provide valuable insights into the potential genetic basis of prenatal organogenesis abnormalities associated with ASD and shed light on the complex interplay between genetic factors and fetal development.
The present invention relates to a whitening cosmetic composition containing a Phyllostachys bambusoides SIEB. et ZUCC. extract and a Phyllostachys pubescens MAZEL extract extracted by using supercritical fluid extraction and, more specifically, the following steps comprises: a step for crushing stem and leaves of a prepared Phyllostachys bambusoides SIEB. et ZUCC. and a prepared Phyllostachys pubescens MAZEL; a step for drying stem and leaves of the crushed Phyllostachys bambusoides SIEB. et ZUCC. and the crushed Phyllostachys pubescens MAZEL; a step for grinding stem and leaves of the dried Phyllostachys bambusoides SIEB. et ZUCC. and the dried Phyllostachys pubescens MAZEL at a predetermined particle size; a step for extracting an active ingredient using supercritical fluid extraction after adding a cosolvent in stem and leaves of the grinded Phyllostachys bambusoides SIEB. et ZUCC. and the grinded Phyllostachys pubescens MAZEL; and a step for concentrating the extracted active ingredient.
Human Experience: In adult pre-marketing clinical studies involving more than 3,350 patients and/or healthy subjects, accidental or intentional acute overdosage of asenapine was identified in 3 patients. Among these few reported cases of overdose, the highest estimated ingestion of asenapine was 400 mg. Reported adverse reactions at the highest dosage included agitation and confusion.

Management of Overdosage: There is no specific antidote to asenapine. The possibility of multiple drug involvement should be considered. An electrocardiogram should be obtained and management of overdose should concentrate on supportive therapy, maintaining an adequate airway, oxygenation and ventilation, and management of symptoms. Consult with a Certified Poison Control Center for up-to-date guidance and advice on the management of overdosage (1-800-222-1222.)

Hypotension and circulatory collapse should be treated with appropriate measures, such as intravenous fluids and/or sympathomimetic agents (epinephrine and dopamine should not be used, since beta stimulation may worsen hypotension in the setting of asenapine-induced alpha blockade). In case of severe extrapyramidal symptoms, anticholinergic medication should be administered. Close medical supervision and monitoring should continue until the patient recovers.
Experimental: 15 healthcare professionals will be recruited for the study. The group includes physiotherapists (PTs), physiotherapist assistants (PTAs), clinical exercise physiologists (EPs), and rehabilitation technicians (RTs), all resident in US and representing the final users of the device. Operators are representative of the final users of the exoskeleton.
The recommended daily dosage for adults and children is 5 mg/kg given as a single infusion. ABELCET ®should be administered by intravenous infusion at a rate of 2.5 mg/kg/h. If the infusion time exceeds 2 hours, mix the contents by shaking the infusion bag every 2 hours. 

Renal toxicity of ABELCET ®, as measured by serum creatinine levels, has been shown to be dose dependent. Decisions about dose adjustments should be made only after taking into account the overall clinical condition of the patient. 

Preparation of Admixture for Infusion:Shake the vial gently until there is no evidence of any yellow sediment at the bottom. Withdraw the appropriate dose of ABELCET ®from the required number of vials into one or more sterile syringes using an 18-gauge needle. Remove the needle from each syringe filled with ABELCET ®and replace with the 5-micron filter needle supplied with each vial. Each filter needle may be used to filter the contents of up to four 100 mg vials. Insert the filter needle of the syringe into an IV bag containing 5% Dextrose Injection USP, and empty the contents of the syringe into the bag. The final infusion concentration should be 1 mg/mL. For pediatric patients and patients with cardiovascular disease the drug may be diluted with 5% Dextrose Injection to a final infusion concentration of 2 mg/mL. Before infusion, shake the bag until the contents are thoroughly mixed. Do not use the admixture after dilution with 5% Dextrose Injection if there is any evidence of foreign matter. Vials are for single use. Unused material should be discarded. Aseptic technique must be strictly observed throughout handling of ABELCET ®, since no bacteriostatic agent or preservative is present. 

DO NOT DILUTE WITH SALINE SOLUTIONS OR MIX WITH OTHER DRUGS OR ELECTROLYTES as the compatibility of ABELCET ®with these materials has not been established. An existing intravenous line should be flushed with 5% Dextrose Injection before infusion of ABELCET ®, or a separate infusion line should be used. DO NOT USE AN IN-LINE FILTER. 

The diluted ready-for-use admixture is stable for up to 48 hours at 2° to 8°C (36° to 46°F) and an additional 6 hours at room temperature.
Corneal Opacities: Dogs receiving oral sumatriptan developed corneal opacities and defects in the corneal epithelium. Corneal opacities were seen at the lowest dosage tested, 2 mg/kg/day, and were present after 1 month of treatment. Defects in the corneal epithelium were noted in a 60-week study. Earlier examinations for these toxicities were not conducted and no-effect doses were not established; however, the relative exposure at the lowest dose tested was approximately 5 times the human exposure after a 100 mg oral dose. There is evidence of alterations in corneal appearance on the first day of intranasal dosing to dogs. Changes were noted at the lowest dose tested, which was approximately one half the maximum single human oral dose of 100 mg on a mg/m2 basis.
<P>PROBLEM TO BE SOLVED: To provide a method for producing a polyclonal antibody against specific antigen, etc.  <P>SOLUTION: A cDNA is prepared from multiple kinds of cells expressing an antibody. Multiple kinds of genes encoding an antibody against a specific antigen are separated from the cDNA to prepare a gene mixture composed of the genes. The gene mixture is brought into contact with a vector to prepare multiple kinds of recombinant vectors containing inserted genes encoding an antibody against a specific antigen and prepare a vector mixture composed of the recombinant vectors. The vector mixture is brought into contact with a host cell to prepare multiple kinds of recombinants containing the introduced recombinant vectors and prepare a recombinant mixture composed of the recombinants. The recombinant mixture is cultured by mix culture and a mixture of multiple kinds of antibodies against a specific antigen is collected from the cultured product.  <P>COPYRIGHT: (C)2007,JPO&INPIT
The present invention pertains to a flow path structure body for forming self-assembling molecular particles. The flow path structure body has a base body and a flow path structure provided to the interior thereof, the flow path structure having a first introduction channel  10  and a second introduction channel  20  that are independent of one another on the upstream side of the flow path structure, and the introduction channels merging at a merging site. The flow path structure has a dilution flow path  40  that is bent three-dimensionally toward the downstream side of the merging site. The dilution flow path  40  has two or more Y structural elements  50  that protrude out in the Y direction and one or more Z structural elements  60  that protrude out in the Z direction within the dilution flow path, and at least two adjacent Y structural elements protrude out alternately in the Y direction. The present invention pertains to a method of producing self-assembling molecular particles, whereby a self-assembling molecule-containing solution and a dilution medium are supplied to the flow path structure body to form self-assembling molecular particles that have encapsulated a substance to be encapsulated. The present invention provides: a method of producing self-assembling molecular nanoparticles that enables precise control of the particle size of self-assembling molecular nanoparticles that have encapsulated an anionic molecule or the like at a high encapsulation rate; and a flow path structure body used for production.
After the proximal gastrectomy, the purse-string suture is tied at the esophagus stump, and the anvil head is inserted into the esophagus stump using an anvil clamp. A Roux-en-Y esophagojejunostomy (E-stomy) is performed by intracorporeal anastomosis with a circular stapler, and the jejunal stump is closed with a linear stapler. Next, side-to-side gastrojejunostomy (G-stomy), 15 cm below the E-stomy, is performed using 2 linear staplers. Finally, end-to-side jejunojejunostomy (J-stomy), 20 cm below the G-stomy, is performed by 2 linear staplers.
The invention discloses a traditional Chinese medicine combination for treating hyperplasia of mammary glands. The combination the active component is made from the raw medicine according to a certain weight percentage: 6.41 to 25.64 percent of radix bupleuri, 9.62 to 38.48 percent of rhizoma cyperi, 3.85 to 15.40 percent of pseudobulubs cremastrae seu pleiones, 1.93 to 7.72 percent of cornu cervi, 12.82 to 51.28 percent of herba leonuri, 9.62 to 38.48 percent of fructus crataegi and 5.77 to 23.08 percent of herba epimedii. The invention also discloses preparation method of the medicine combination. The medicine combination of the invention has the effect of warming and recuperating liver and kidney, regulating qi and activating blood, and reducing phlegm and resolving masses. The medicine combination also produces down-regulation effect on estrogen receptor, thus addressing both symptoms and root cause, improving the curative effect, reducing recurrence and providing good treatment of hyperplasia of mammary glands which are caused by deficiency of liver and kidney, imbalance of chong and ren channels, and stagnation of qi and blood. The medicine combination of the invention has the advantages of controllable quality, small dose, convenient operation and carrying, and definite therapeutic effect, and is easy for large industrialization production.
A drug-delivery system is described which can serve as a platform for the topical delivery of a wide variety of therapeutic agents to the skin. Specifically, a topical external analgesic gel contains ketoprofen, a skin penetration enhancer/cosolvent, a thickening agent and a base to adjust pH. The formulation uses a relatively small number of safe components and is easy to prepare with a high yield of finished product. The chemical stability of ketoprofen in the gel and the physical stability of the gel itself ensure a satisfactory shelf- life for the product. The gel is aesthetically pleasing (i.e., easy water-washability, non-irritating to skin, non-staining of clothing, etc.) and has proven to provide rapid relief of musculoskeletal pain, thereby helping to ensure patient compliance.
PROBLEM TO BE SOLVED: To obtain the subject new compound which is a compound, having a phenoxypyrimidine skeleton and inhibiting actions on the Na<+> /Ca<2+> exchange system and useful as a therapeutic and a prophylactic agents for ischemic heat diseases, ischemic brain diseases or ischemic renal diseases or the like. SOLUTION: This phenoxypyrimidine derivative is represented by formula I  R<1> m denotes a halogen [(m) is an integer of 0-5]; R<2> is H or a lower alkyl; R<3> is H, a lower alkyl, a lower alkoxy, a halogen or the like} or its salt, e.g. N-[2-[4-(benzyloxy)phenoxyl-5-pyridyl]methoxyacetamide. The compound represented by formula I is obtained by reacting, e.g. a compound represented by formula II with a compound represented by formula III (Y is F, Cl or Br) in the presence of a base, then reducing the resultant compound represented by formula IV and subsequently acylating the prepared compound. Since the compound represented by formula I is capable of effectively inhibiting the Na<+> /Ca<2+> exchange system, the excessive accumulation of Ca<2a> in cells can be suppressed to prevent the cytotoxicity after ischemia and reperfusion.
FIELD: veterinary science, medicine. SUBSTANCE: preparation comprises actively acting substance based on inorganic compounds and exhibits the following composition: mas. p. p: glauconite concentrate ADB, 25-75; forming substance, 2.7-3.7; distilled water, up to 1000 ml. Agar-agar and/or pectin, and/or gelatin, and/or carboxymethylcellulose are used as forming substances. Preparation provides the enhancement of general resistance of living body and normalization of functions of gastroenteric tract due to its ability to absorb and eliminate harmful and toxic substances from body. Medicinal preparation can be used for prophylaxis and treatment of gastroenteric tract sicknesses. EFFECT: valuable medicinal properties of preparation. 2 cl, 12 ex
The retina is a light-sensitive layer at the back of your eye that captures images. When light enters your eye, the retina turns it into signals that travel to your brain, helping you see. It's crucial for clear vision. When a retinal tear forms at the back of your eye, it can cause the fluid inside your eye to leak, leading to the retina peeling away and cause vision problems including blindness.

Retinal Thermofusion (RTF) uses a laser device called iSeelr™ to first dehydrate the fluid buildup around the retina and then laser treatment to seal the retina back in its place. The device was developed by Photofuse Pty Ltd and method validated in a laboratory with the Centre for Eye Research Australia and The University of Melbourne, Victoria, Australia.This clinical trial involves recruiting 10 participants with rhegmatogenous retinal detachment who will receive the treatment and be closely followed with 7 study visits over a three month period. This will allow us to assess the safety and performance of RTF. This research is being Sponsored by Photofuse Pty Ltd and is funded by the US Department of Defense (Award W81XWH-21-1-0730).
The intervention group will receive nicotine replacement therapy (NRT) sampling and medication counseling. The nurse will help the subject to decide which NRT product (patch or gum) he/she can use and advise how to use the NRT based on his/her smoking habit and amount of cigarette consumption. In addition, the nurse will deliver medication counselling which addresses five main components: (1) the benefits for using NRT in quitting, (2) withdrawal symptoms due to smoking cessation, (3) side effects of NRT, (4) instructions for using NRT, and (5) making appointments for TWGHs SC clinics. Afterwards, the participant will receive 1-week free NRT, an education card about NRT and a one-page leaflet provided by the SC clinics.
Subjects with mild renal impairment. eGFR (by MDRD equation) range 60 - 89 mL/min/1.73 m2 as determined at Screening.
Apparatus and associated methods relate to scheduling service provider and service consumer interactions based on determining service consumer scores, service provider scores, and service time slot scores predicting outcomes for provider service to a consumer in a time slot, and automatically adapting demand and supply matched as functions of the scores. In an illustrative example, the service consumer may be a client. The service provider may be, for example, a professional offering service in an available time slot. In some examples, individual client, provider, and time slot scores may be calculated as functions of predictive variables associated with a client population and the provider practice environment. In some embodiments, scores may be probability estimates of show, no-show, delay, or cancellation. Various embodiments may advantageously determine schedules with maximum likelihood of full occupancy to optimize resource utilization and revenue expenditure, based on collectively optimizing client, provider, and time slot probability estimates.